RxSight, Inc.

NasdaqGM RXST

RxSight, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024

RxSight, Inc. Net Cash Used For Investing Activities is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: RXST

RxSight, Inc.

CEO	Dr. Ronald M. Kurtz M.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	100 Columbia
Employees	374
Sector	Consumer Discretionary
Industries Eyewear

Description

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Key trends

Past 5 years